KURA vs AGIO vs PTCT vs IMVT vs IQV

For growth investors, PTC Therapeutics, Inc.

(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate Kura Oncology, Inc. (KURA) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 8. 3x versus IQVIA Holdings Inc. at 22. 8x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -64. 4% for Kura Oncology, Inc. (KURA). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus AGIO's -42. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc.

(AGIO) is the lower-risk stock at 1. 12β versus Kura Oncology, Inc. 's 1. 66β — meaning KURA is approximately 49% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PTC Therapeutics, Inc.

(PTCT) is pulling ahead at 114. 5% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — KURA leads at 99. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KURA: 193.

2% to $27. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +733. 2% 10Y return). Kura Oncology, Inc. (KURA) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +733. 2%, KURA: +245. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KURA is a small-cap high-growth stock; AGIO is a small-cap high-growth stock; PTCT is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.